Medmarc Insurance Company
Medmarc, established in 1979 by the healthcare technology industry, is dedicated to providing superior liability insurance protection and risk management solutions to the life sciences and medical technology sectors. The company supports the development, testing, and delivery of medical products that enhance and save lives. Through collaboration with its parent company, ProAssurance, and strategic alliances, Medmarc offers innovative healthcare liability insurance solutions tailored to the evolving needs of life sciences companies.
Industries
N/A
Nr. of Employees
small (1-50)
Medmarc Insurance Company
4795 Meadow Wood Lane, Suite 335 West, Chantilly, VA 20151-2219
Products
Products Liability (Products/Completed Operations) policy
Policy covering third‑party bodily injury and property damage claims arising from products and completed operations for life sciences companies, with options for worldwide defense, recall/withdrawal endorsements and additional insured extensions.
Clinical Trials Liability coverage
Policy addressing exposures arising from clinical trial activities, including participant medical expense coverage, protection for IRBs and ethics committees, and capability to arrange locally admitted foreign policies when required by local regulation.
Manufacturers' Errors & Omissions policy
Policy covering economic injury to third parties from errors or omissions in manufacturing, servicing or contractual obligations, including data corruption and recall‑related economic loss.
Product withdrawal / recall endorsement
Endorsement covering expenses to remove a product from the marketplace for safety reasons, including communication and direct recall costs subject to policy terms and exclusions.
Products Liability (Products/Completed Operations) policy
Policy covering third‑party bodily injury and property damage claims arising from products and completed operations for life sciences companies, with options for worldwide defense, recall/withdrawal endorsements and additional insured extensions.
Clinical Trials Liability coverage
Policy addressing exposures arising from clinical trial activities, including participant medical expense coverage, protection for IRBs and ethics committees, and capability to arrange locally admitted foreign policies when required by local regulation.
Manufacturers' Errors & Omissions policy
Policy covering economic injury to third parties from errors or omissions in manufacturing, servicing or contractual obligations, including data corruption and recall‑related economic loss.
Product withdrawal / recall endorsement
Endorsement covering expenses to remove a product from the marketplace for safety reasons, including communication and direct recall costs subject to policy terms and exclusions.
Services
Underwriting and placement of products/completed operations liability coverage tailored for medical technology and life sciences manufacturers and distributors, with policy features addressing side effects/adverse reactions and worldwide defense where claims are brought, subject to sanctions or embargoes.
Insurance programs covering clinical trial operations and liabilities, including automatic inclusion for trials initiated during a policy period, medical expense coverage for participants, compassionate‑use scenarios, no additional audit charges for trial activity, and ability to arrange locally admitted foreign coverage through partner networks.
E&O policies for economic injury to third parties arising from negligent acts in design, manufacture, distribution or services, covering data loss/corruption, loss of use of data, and recall‑related economic damages.
Operational risk assessments, FDA/regulatory compliance guidance, and targeted training to reduce product liability exposures, offered on a fee‑for‑service basis or as a policyholder benefit.
Specialized claims handling and coordination of national and international defense counsel, with structured reporting, investigation support and litigation strategy to resolve products liability matters.
Underwriting and placement of products/completed operations liability coverage tailored for medical technology and life sciences manufacturers and distributors, with policy features addressing side effects/adverse reactions and worldwide defense where claims are brought, subject to sanctions or embargoes.
Insurance programs covering clinical trial operations and liabilities, including automatic inclusion for trials initiated during a policy period, medical expense coverage for participants, compassionate‑use scenarios, no additional audit charges for trial activity, and ability to arrange locally admitted foreign coverage through partner networks.
E&O policies for economic injury to third parties arising from negligent acts in design, manufacture, distribution or services, covering data loss/corruption, loss of use of data, and recall‑related economic damages.
Operational risk assessments, FDA/regulatory compliance guidance, and targeted training to reduce product liability exposures, offered on a fee‑for‑service basis or as a policyholder benefit.
Specialized claims handling and coordination of national and international defense counsel, with structured reporting, investigation support and litigation strategy to resolve products liability matters.
Expertise Areas
- Products liability underwriting and placement
- Clinical trial liability and international placement
- Manufacturers' errors & omissions for life sciences
- Risk management and regulatory compliance consulting
Key Technologies
- Online broker/insured portal for claims and loss runs
- Electronic fillable policy applications with e‑signature
- International local‑admitted placement partner networks
- Webinar and digital content delivery for training/resources
News & Updates
CSSi LifeSciences™ and MTEC will host the annual Partnering Forum during the JP Morgan Healthcare Conference in January 2025 at the Hilton San Francisco Union Square hotel and online in February 2025.
The FDA has appointed a new director for the Center for Devices and Radiological Health (CDRH).
A study published in the Annals of Internal Medicine disclosed an association between false positives in mammography and screening compliance.
This article examines the products liability risks associated with the FDA rule on IRB waivers for minimal risk trials.
CSSi LifeSciences™ and MTEC will host the annual Partnering Forum during the JP Morgan Healthcare Conference in January 2025 at the Hilton San Francisco Union Square hotel and online in February 2025.
The FDA has appointed a new director for the Center for Devices and Radiological Health (CDRH).
A study published in the Annals of Internal Medicine disclosed an association between false positives in mammography and screening compliance.
This article examines the products liability risks associated with the FDA rule on IRB waivers for minimal risk trials.